Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [3]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [3]. Group 2: Next Steps for Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a well-established securities litigation firm, has a strong track record in securing recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant stock price drop [1][3][4]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Performance Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's lack of competitive efficacy, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Accessibility StatementSkip Navigation WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025Â to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the pas ...

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 13 ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences compared to traditional monoclonal antibody treatments [4]. Allegations and Stock Impact - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted nearly 90%, from $61.99 to $6.24 per share [6].

New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177026&wire=5&utm_campaign=14or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 12, 2025 4:21 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Per ...

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than Januar ...